Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Argus Health
US Department of Justice
Healthtrust
Federal Trade Commission
Chinese Patent Office

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,211,889

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,211,889 protect, and when does it expire?

Patent 8,211,889 protects TAVALISSE and is included in one NDA.

This patent has thirty patent family members in twenty-three countries.

Summary for Patent: 8,211,889
Title:Prodrugs of 2,4-pyrimidinediamine compounds and their uses
Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Inventor(s): Singh; Rajinder (Belmont, CA), Bhamidipati; Somasekhar (Foster City, CA), Sun; Thomas (Fremont, CA), Stella; Valentino J. (Lawrence, KS)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:13/349,194
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,211,889

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-001 Apr 17, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Rigel Pharms Inc TAVALISSE fostamatinib disodium TABLET;ORAL 209299-002 Apr 17, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,211,889

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 451381 ➤ Sign Up
Australia 2006206458 ➤ Sign Up
Brazil PI0606318 ➤ Sign Up
Canada 2591948 ➤ Sign Up
China 101115761 ➤ Sign Up
Cyprus 1109888 ➤ Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Deloitte
Queensland Health
Federal Trade Commission
Express Scripts
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.